Id: acc0008
Group: 1sens
Protein: alpha-tubulin
Gene Symbol: TUBA1B
Protein Id: P68363
Protein Name: TBA1B_HUMAN
PTM: acetylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype: NSCLC
Disease Cellline: A549
Disease Info:
Drug: paclitaxel
Drug Info: "Paclitaxel is a plant-derived alkaloid and potent antineoplastic agent that stabilizes microtubules to inhibit cancer cell division, primarily used in the treatment of ovarian, breast, and lung cancers. "
Effect: increase
Effect Info: Caffeine reduces the inhibitory effect of paclitaxel on tumor growth by downregulating alpha-tubulin acetylation.
Note:
Score: 5.0
Pubmed(PMID): 32580047
Sentence Index:
Sentence:

Sequence & Structure:

MRECISIHVGQAGVQIGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFNTFFSETGAGKHVPRAVFVDLEPTVIDEVRTGTYRQLFHPEQLITGKEDAANNYARGHYTIGKEIIDLVLDRIRKLADQCTGLQGFLVFHSFGGGTGSGFTSLLMERLSVDYGKKSKLEFSIYPAPQVSTAVVEPYNSILTTHTTLEHSDCAFMVDNEAIYDICRRNLDIERPTYTNLNRLISQIVSSITASLRFDGALNVDLTEFQTNLVPYPRIHFPLATYAPVISAEKAYHEQLSVAEITNACFEPANQMVKCDPRHGKYMACCLLYRGDVVPKDVNAAIATIKTKRSIQFVDWCPTGFKVGINYQPPTVVPGGDLAKVQRAVCMLSNTTAIAEAWARLDHKFDLMYAKRAFVHWYVGEGMEEGEFSEAREDMAALEKDYEEVGVDSVEGEGEEEGEEY

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
TUBA1B MIRVETUXIMAB SORAVTANSINE Tubulin inhibitor 4 - peritoneal neoplasm FDA
TUBA1B MIRVETUXIMAB SORAVTANSINE Tubulin inhibitor 4 - malignant epithelial tumor of ovary FDA
TUBA1B MIRVETUXIMAB SORAVTANSINE Tubulin inhibitor 4 - fallopian tube neoplasm FDA
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed bladder tumor ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 - neoplasm ATC
TUBA1B VINFLUNINE Tubulin inhibitor 3 - neoplasm ATC
TUBA1B OMBRABULIN Tubulin inhibitor 3 Completed sarcoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Terminated non-small cell lung carcinoma ClinicalTrials
TUBA1B PLINABULIN Tubulin inhibitor 3 Completed non-small cell lung carcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status ovarian serous adenocarcinoma ClinicalTrials
TUBA1B TUSAMITAMAB RAVTANSINE Tubulin inhibitor 3 Active, not recruiting non-small cell lung carcinoma ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Active, not recruiting urogenital neoplasm ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed urogenital neoplasm ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status undifferentiated carcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status ovarian mucinous adenocarcinoma ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed urothelial carcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status ovarian clear cell adenocarcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status Primary Peritoneal Serous Adenocarcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status Fallopian Tube Serous Adenocarcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status Ovarian Transitional Cell Carcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status Malignant Ovarian Brenner Tumor ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed urinary bladder cancer ClinicalTrials
ClinicalTrials
TUBA1B PLINABULIN Tubulin inhibitor 3 Completed neutropenia ClinicalTrials
TUBA1B PLINABULIN Tubulin inhibitor 3 Active, not recruiting neutropenia ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed head and neck carcinoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: